Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gyre Therapeutics (GYRE) Change in Acquisitions & Divestments: 2009-2022

Historic Change in Acquisitions & Divestments for Gyre Therapeutics (GYRE) over the last 14 years, with Dec 2022 value amounting to $2.5 million.

  • Gyre Therapeutics' Change in Acquisitions & Divestments was N/A to $11.2 million in Q1 2025 from the same period last year, while for Mar 2025 it was $24.1 million, marking a year-over-year change of. This contributed to the annual value of $2.5 million for FY2022, which is 94.89% down from last year.
  • Gyre Therapeutics' Change in Acquisitions & Divestments amounted to $2.5 million in FY2022, which was down 94.89% from $49.0 million recorded in FY2021.
  • Gyre Therapeutics' Change in Acquisitions & Divestments' 5-year high stood at $157.4 million during FY2019, with a 5-year trough of $2.5 million in FY2022.
  • Over the past 3 years, Gyre Therapeutics' median Change in Acquisitions & Divestments value was $49.0 million (recorded in 2021), while the average stood at $53.0 million.
  • Per our database at Business Quant, Gyre Therapeutics' Change in Acquisitions & Divestments surged by 794.87% in 2018 and then crashed by 94.89% in 2022.
  • Gyre Therapeutics' Change in Acquisitions & Divestments (Yearly) stood at $128.0 million in 2018, then grew by 23.03% to $157.4 million in 2019, then slumped by 31.68% to $107.6 million in 2020, then tumbled by 54.42% to $49.0 million in 2021, then tumbled by 94.89% to $2.5 million in 2022.